Latest Regulatory Filings News

Echo IQ has completed its presentation to the CPT Editorial Panel for a Category III CPT code for EchoSolv AS, with a decision expected from the American Medical Association in the coming weeks. Meanwhile, the company is advancing US deployments and FDA clearance efforts.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Warriedar Resources has received ASIC approval to delay its 2025 AGM until January 2026, allowing time for critical shareholder votes on proposed share option schemes tied to a Capricorn Metals acquisition.

News Corporation has completed a $450 million secondary offering of Class B shares by key Murdoch family trusts, alongside a new stockholders agreement that reshapes family voting power and share transfer rights.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

The Australian Taxation Office has issued a binding ruling detailing the capital gains tax treatment for Spartan Resources shareholders following Ramelius Resources' acquisition via a Scheme of Arrangement. Eligible shareholders can elect partial scrip-for-scrip rollover relief, deferring tax on the share component of their proceeds.

Xamble Group Limited’s XGLO securities have been suspended from trading pending compliance with ASX listing rules, raising questions about the company’s regulatory standing.

Warriedar Resources has secured a crucial ASX waiver allowing the cancellation of 5 million unlisted options without shareholder approval, smoothing the path for Capricorn Metals’ acquisition scheme.

Alligator Energy has lodged a Prospectus for Placement Options following its June 2025 capital raise, setting the stage for potential shareholder dilution and future funding opportunities.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Ian Ferrier, founder and long-standing board member of Energy One Limited, has sold a portion of his shares but reassures investors of his ongoing commitment to the company.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.